JP2012505239A - 心臓治療用の多血小板血漿製剤 - Google Patents

心臓治療用の多血小板血漿製剤 Download PDF

Info

Publication number
JP2012505239A
JP2012505239A JP2011531182A JP2011531182A JP2012505239A JP 2012505239 A JP2012505239 A JP 2012505239A JP 2011531182 A JP2011531182 A JP 2011531182A JP 2011531182 A JP2011531182 A JP 2011531182A JP 2012505239 A JP2012505239 A JP 2012505239A
Authority
JP
Japan
Prior art keywords
concentration
composition
prp
disease
whole blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011531182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505239A5 (enExample
Inventor
クマール ミシュラ，アラン
Original Assignee
バイオパラドックス，リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオパラドックス，リミテッド ライアビリティー カンパニー filed Critical バイオパラドックス，リミテッド ライアビリティー カンパニー
Publication of JP2012505239A publication Critical patent/JP2012505239A/ja
Publication of JP2012505239A5 publication Critical patent/JP2012505239A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
JP2011531182A 2008-10-09 2009-10-08 心臓治療用の多血小板血漿製剤 Pending JP2012505239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10407408P 2008-10-09 2008-10-09
US61/104,074 2008-10-09
PCT/US2009/060061 WO2010042762A1 (en) 2008-10-09 2009-10-08 Platelet rich plasma formulations for cardiac treatments

Publications (2)

Publication Number Publication Date
JP2012505239A true JP2012505239A (ja) 2012-03-01
JP2012505239A5 JP2012505239A5 (enExample) 2012-11-22

Family

ID=42099040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531182A Pending JP2012505239A (ja) 2008-10-09 2009-10-08 心臓治療用の多血小板血漿製剤

Country Status (4)

Country Link
US (6) US8440459B2 (enExample)
EP (1) EP2337617A4 (enExample)
JP (1) JP2012505239A (enExample)
WO (1) WO2010042762A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022239870A1 (ja) * 2021-05-14 2022-11-17 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP7175055B1 (ja) 2021-05-14 2022-11-18 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP2023517543A (ja) * 2020-03-05 2023-04-26 ノヴィステム ソシエタ ペル アチオニ 創傷治癒および組織再生に有用な血液製剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US7678780B2 (en) * 2003-12-29 2010-03-16 Allan Mishra Method of treating cancer using platelet releasate
US7462268B2 (en) 2004-08-20 2008-12-09 Allan Mishra Particle/cell separation device and compositions
US20100112081A1 (en) * 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
JP2012505239A (ja) 2008-10-09 2012-03-01 バイオパラドックス，リミテッド ライアビリティー カンパニー 心臓治療用の多血小板血漿製剤
US20120171181A1 (en) * 2009-09-04 2012-07-05 Allan Mishra Compositions and minimally invasive methods for treating cancer
US20130017180A1 (en) * 2010-04-05 2013-01-17 Allan Mishra Platelet rich plasma formulations
US9164079B2 (en) * 2011-03-17 2015-10-20 Greyledge Technologies Llc Systems for autologous biological therapeutics
WO2014126931A1 (en) * 2013-02-15 2014-08-21 Victor Steven Stable platelet- rich-plasma compositions and methods of use
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US11340212B2 (en) * 2017-04-21 2022-05-24 Greyledge Technologies, Llc Biological fluid composition categorization method
US20180353542A1 (en) * 2017-06-08 2018-12-13 Allan Kumar Mishra Mononuclear-rich, platelet-rich plasma compositions and methods of use thereof
CN114667151B (zh) * 2019-11-04 2025-05-23 万能溶剂有限公司 用于肌肉再生的血浆级分
WO2024040248A2 (en) * 2022-08-19 2024-02-22 The Regents Of The University Of California Biomaterial for wound regenerative healing
WO2024249800A1 (en) * 2023-06-01 2024-12-05 Alkahest, Inc. Compositions of blood plasma fractions and blood plasma subfractions and their use in treatment of disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127382A1 (en) * 2004-08-20 2006-06-15 Allan Mishra Particle/cell separation device and compositions
WO2007112135A2 (en) * 2006-03-23 2007-10-04 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20080045964A1 (en) * 2006-08-16 2008-02-21 Allan Mishra Device for cartilage repair
US20080089867A1 (en) * 2006-10-13 2008-04-17 Brian Fernandes Method of increasing retention, survival and proliferation of transplanted cells in vivo

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414108A (en) * 1980-05-09 1983-11-08 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and method for continuous countercurrent extraction and particle separation
CA1244774A (en) 1983-11-09 1988-11-15 Thomas Jefferson University Medium for storing blood platelets
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US5178883A (en) * 1984-11-29 1993-01-12 Regents Of The University Of Minnesota Method for promoting hair growth
US4957742A (en) * 1984-11-29 1990-09-18 Regents Of The University Of Minnesota Method for promoting hair growth
US5428008A (en) * 1989-04-14 1995-06-27 Prp, Inc. Therapeutic composition of micellar structures capable of promoting hemotasis
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
IL95641A0 (en) 1989-09-15 1991-06-30 Curative Tech Inc Preparation of a platelet releasate product
US5147776A (en) * 1990-02-26 1992-09-15 University Of Iowa Research Foundation Use of 2,5-anhydromannitol for control of pH during blood storage
US5641622A (en) * 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
US5785869A (en) * 1992-02-10 1998-07-28 Baxter International Inc. Method for creating a leukocyte rich sample from a mixed population of blood cells
US5403272A (en) * 1992-05-29 1995-04-04 Baxter International Inc. Apparatus and methods for generating leukocyte free platelet concentrate
DE69332756T2 (de) * 1992-05-29 2004-02-19 University Of North Carolina At Chapel Hill Im immobilisierten zustand getrocknete pharmazeutische verträgliche menschliche blutplättchen
US5494590A (en) * 1992-06-11 1996-02-27 Becton Dickinson Method of using anticoagulant solution in blood separation
EP0720658A1 (en) * 1993-09-23 1996-07-10 E.I. Du Pont De Nemours And Company An electrophoretic method for the isolation and separation of microorganisms
US5662813A (en) * 1994-10-21 1997-09-02 Bioseparations, Inc. Method for separation of nucleated fetal erythrocytes from maternal blood samples
US7169547B2 (en) * 1994-12-05 2007-01-30 New York Blood Center, Inc. High concentration white blood cells as a therapeutic product
US5789147A (en) * 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5585007A (en) * 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US5614204A (en) * 1995-01-23 1997-03-25 The Regents Of The University Of California Angiographic vascular occlusion agents and a method for hemostatic occlusion
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5733545A (en) * 1995-03-03 1998-03-31 Quantic Biomedical Partners Platelet glue wound sealant
US5834418A (en) * 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
DE19781869T1 (de) * 1996-04-30 2000-03-16 Medtronic Inc Verfahren zur Herstellung eines autologen Fibrin-Blutstillungsmittels
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
FR2781485B1 (fr) * 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
ATE324831T1 (de) 1998-08-26 2006-06-15 Neomend Inc Kit zur in-situ-erzeugung chemisch verbundener mechanischer barrieren oder abdeckstrukturen für eine punktionsstelle in einem blutgefäss
US6432119B1 (en) * 1999-03-17 2002-08-13 Angiotrax, Inc. Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials
DE19960504A1 (de) * 1999-12-15 2001-08-16 Curasan Ag Regenerationsmittel
WO2001078652A2 (en) * 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20020058030A1 (en) * 2000-05-03 2002-05-16 Eligix, Inc. Whole blood separator apparatus and method of use
US6922685B2 (en) * 2000-05-22 2005-07-26 Mci, Inc. Method and system for managing partitioned data resources
US6554801B1 (en) * 2000-10-26 2003-04-29 Advanced Cardiovascular Systems, Inc. Directional needle injection drug delivery device and method of use
US7740623B2 (en) * 2001-01-13 2010-06-22 Medtronic, Inc. Devices and methods for interstitial injection of biologic agents into tissue
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US20030152639A1 (en) * 2001-07-03 2003-08-14 Calvin Britton Novel wound healing composition not containing bovine-derived activating reagents
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
US7201848B2 (en) * 2001-12-05 2007-04-10 Gambro Bct, Inc. Methods and apparatus for separation of particles
US7211191B2 (en) * 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
US7241281B2 (en) * 2002-04-08 2007-07-10 Thermogenesis Corporation Blood component separation method and apparatus
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
JP2005523128A (ja) 2002-04-24 2005-08-04 インターポア・オルソペディックス 血液分離及び濃縮システム
US20030205538A1 (en) * 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
US6905612B2 (en) * 2003-03-21 2005-06-14 Hanuman Llc Plasma concentrate apparatus and method
US20040182795A1 (en) * 2003-03-21 2004-09-23 Randel Dorian Apparatus and method for concentration of plasma from whole blood
US6982038B2 (en) * 2002-06-14 2006-01-03 Medtronic, Inc. Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma
US20070225614A1 (en) * 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
EP2359689B1 (en) * 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
US7291450B2 (en) * 2003-03-28 2007-11-06 Smith & Nephew, Inc. Preparation of a cell concentrate from a physiological solution
WO2005079515A2 (en) * 2004-02-19 2005-09-01 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
US20060095121A1 (en) * 2004-10-28 2006-05-04 Medtronic Vascular, Inc. Autologous platelet gel on a stent graft
WO2006086201A2 (en) * 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
US8316434B2 (en) * 2005-02-23 2012-11-20 At&T Intellectual Property I, L.P. Centralized access control system and methods for distributed broadband access points
US20070172472A1 (en) * 2005-06-23 2007-07-26 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007002554A2 (en) * 2005-06-23 2007-01-04 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
JP2010509943A (ja) * 2006-09-28 2010-04-02 チルドレンズ メディカル センター コーポレーション 組織を修復する方法およびそのためのコラーゲン生成物
US20090053208A1 (en) * 2007-08-20 2009-02-26 Medtronic Vascular, Inc. Methods and Systems for Improving Tissue Perfusion
WO2010005557A2 (en) * 2008-07-07 2010-01-14 Arteriocyte Medical Systems, Inc. Biological therapeutic compositions and methods thereof
US20100112081A1 (en) * 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
JP2012505239A (ja) 2008-10-09 2012-03-01 バイオパラドックス，リミテッド ライアビリティー カンパニー 心臓治療用の多血小板血漿製剤
US8177072B2 (en) * 2008-12-04 2012-05-15 Thermogenesis Corp. Apparatus and method for separating and isolating components of a biological fluid
US8921037B2 (en) * 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
US20130017180A1 (en) 2010-04-05 2013-01-17 Allan Mishra Platelet rich plasma formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127382A1 (en) * 2004-08-20 2006-06-15 Allan Mishra Particle/cell separation device and compositions
WO2007112135A2 (en) * 2006-03-23 2007-10-04 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20080045964A1 (en) * 2006-08-16 2008-02-21 Allan Mishra Device for cartilage repair
US20080089867A1 (en) * 2006-10-13 2008-04-17 Brian Fernandes Method of increasing retention, survival and proliferation of transplanted cells in vivo

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517543A (ja) * 2020-03-05 2023-04-26 ノヴィステム ソシエタ ペル アチオニ 創傷治癒および組織再生に有用な血液製剤
WO2022239870A1 (ja) * 2021-05-14 2022-11-17 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP7175055B1 (ja) 2021-05-14 2022-11-18 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP2022176421A (ja) * 2021-05-14 2022-11-29 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法

Also Published As

Publication number Publication date
US8440459B2 (en) 2013-05-14
EP2337617A4 (en) 2013-06-12
US20130243879A1 (en) 2013-09-19
US20200179455A1 (en) 2020-06-11
US20120093941A1 (en) 2012-04-19
US20170274015A1 (en) 2017-09-28
EP2337617A1 (en) 2011-06-29
WO2010042762A1 (en) 2010-04-15
US8444969B2 (en) 2013-05-21
US20220313739A1 (en) 2022-10-06
US20100092444A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
US20220313739A1 (en) Platelet rich plasma formulations and use thereof
US20220195391A1 (en) Platelet-rich plasma compositions and methods of preparation
Karantalis et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy
US20230129268A1 (en) Platelet rich plasma formulations
US20240082301A1 (en) Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
Mocini et al. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting
JP2010285440A (ja) 治療複合物
US20250213613A1 (en) Mononuclear-rich, platelet-rich plasma compositions and methods of use thereof
US20140329322A1 (en) Method of differentiating glioblastoma cells
Kaeser et al. Autologous adult cortical cell transplantation enhances functional recovery following unilateral lesion of motor cortex in primates: a pilot study
Dzhyvak et al. Potentials and impact of platelet-rich plasma (PRP) on the regenerative properties of muscle tissue.
US20100233282A1 (en) Device and methods for delivery of bioactive materials to the right side of the heart
JP6525889B2 (ja) 自己骨髄由来の幹細胞の迅速な注入
Spadaccio et al. In situ electrostimulation drives a regenerative shift in the zone of infarcted myocardium
Sadraddin Antiarrhythmic effect of human bone marrow-dereived CD271+ mesenchymal stem cells tested in vivo using a new infarction-re-infarction mouse model
US20120171181A1 (en) Compositions and minimally invasive methods for treating cancer
WO2021038275A1 (en) Activated mesenchymal stem cells for treating limb ischemia
Humans Myocardial Cellular Implantation: Scaling
JP2009507522A (ja) 損傷のある心臓組織を処置する方法およびシステム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121002

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140507